Home / Healthcare/ FDA approves two new HIV drugs from Merck

FDA approves two new HIV drugs from Merck


Comments / {{hitsCtrl.values.hits}} Views / Monday, 3 September 2018 00:00


Reuters: Merck and Co Inc. said on Thursday the US Food and Drug Administration approved two of its HIV oral drugs, nearly two months ahead of schedule.

The drugs have been approved to treat adults with the most common strain of the virus, HIV-1, and target patients who have received no prior antiretroviral treatment, Merck said.

Delstrigo, a once-a-day combination tablet, has been approved with a boxed warning, the agency’s strictest, to flag risk of worsening hepatitis B infection.

Pifeltro, the second drug, is an oral medicine to be administered in combination with other antiretrovirals, Merck said.

Merck said it expects to stock both the treatments through wholesalers within a month.

More than 70 million people have been infected with the HIV virus and about 35 million have died since the beginning of the epidemic, according to the World Health Organization.

There is no vaccine to prevent HIV/AIDS with current treatments only helping patients to manage the disease. However, the fast-mutating virus has proved a challenge to the medical community as it often develops resistance to existing medicines.

Gilead Sciences and GlaxoSmithKline have dominated the market for HIV/AIDS treatments and sell therapies that generate billions of dollars.

 


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Assessment of fitness and propriety of directors and officers

Friday, 13 December 2019

In the early ’80s, a businessman turned financier from the hill capital started a public deposit canvassing drive by offering 20% interest per month. The depositors were offered on the spot payment of 20% as interest for the first month for their d


How to select top officials to public corporations

Friday, 13 December 2019

It is commendable that the President wants to select suitable decision-makers to public corporations without them being mere and ad hoc political appointments. However, the process thus far seems somewhat weak. Various people are complaining about th


De-stigmatising sexuality education for gender equality – it is a right

Friday, 13 December 2019

International Day for the Elimination of Violence against Women, which fell on 25 November, started the 16 Days of Activism against Gender-Based Violence. It is an annual international campaign that runs for 16 days until 10 December (Human Rights


Presidency and Sangha: virtuous or villainous duo?

Thursday, 12 December 2019

President GR should be ever indebted to the Sangha, because without its tireless canvassing he would not have achieved what he did on 16 November. Given the volatile ethno-religious cleavages and unpredictably shifting alliances in the country, it wa


Columnists More